Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
30 participants
INTERVENTIONAL
2008-05-31
2009-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Over the past 5 years since its introduction, our center and others have researched methods to make the MAD both more tolerable and efficacious. Important clues came in 2007, in which an initial carbohydrate limit of 10 grams per day was compared to 20 grams per day in a randomized , prospective, crossover design. Although the hypothesis was that these two carbohydrate limits were equivalent, this was only true after the 3-month crossover period. At diet onset, there was a significantly higher likelihood of a \>50% seizure reduction when a stricter, 10 grams/day MAD was used (60% vs. 10%, p=0.03). Ketosis was higher in that group at 1 month as well, similar to previous findings that the 1-month ketosis levels correlated with efficacy. These results suggested that a stricter, higher ketotic, start to the MAD was important - although loosening restrictions after 1-3 months was also reasonable and did not adversely affect seizure control.
That same year, a research study from South Korea evaluating the initial ratio (3:1 vs. 4:1) of the traditional ketogenic diet in a similar randomized, crossover design found identical results. A 4:1 initial ketogenic diet ratio was correlated with a higher likelihood of seizure freedom (55% vs. 31%, p\<0.05), although ketosis at 3 months was not different. After 3 months, reducing to 3:1 did not lead to reduced seizure control in any of their children.
Recent results using the KD from our center and Chicago Memorial also confirm that the initial month of the KD may be the most crucial. In this study of 99 children on the traditional KD, nearly 90% of children who do respond to the KD do so within the first 28 days. This study suggests that early KD titration to improve efficacy is important.
The results from all of this data within the past year all confirm that the first month of either the MAD or KD may be the most critical. In addition, there is some suggestion that higher ketone levels at 1 month do correlate with better seizure reduction. Therefore, a strict, highly ketotic initial month of dietary therapy may result in better seizure reduction. Realizing that loosening of restrictions will automatically occur after one month, this "tough month" approach is likely to be followed in a compliant manner by most parents knowing it is time-limited.
What is the best way to then achieve higher ketosis levels initially? One option is to fast children before starting the MAD. However, this approach raises concerns regarding hypoglycemia and acidosis, especially in the setting of an outpatient approach, as is typically used for starting the MAD. Some families specifically ask for the MAD to avoid an admission or fasting period. Another option would be to give the KD first, then switch to the MAD after one month. However, the significant time and financial burden involved in a KD admission and training would decrease interest in the MAD approach by families contacting our center, and not truly test the MAD effectiveness as a primary therapy. Other potential ways to increase ketosis include carnitine supplementation, MCT oil inclusion, and calorie restriction. All of these options, however, have their own financial and safety implications.
Our proposal, therefore, is to use the 4:1 KetoCal®, and its proven ability to induce high levels of ketosis, as a partial supplement to the MAD. Our concept is to use this supplement for only the first month to boost ketosis and improve seizure control, as data suggests that this may be the key and only important time period. After this study is completed, it would be acceptable for a family to use KetoCal® as a periodic supplement to help with meal creation, should they wish to do so.
\*\*The study involves 3 trips to Baltimore (travel not covered) over 2 months (baseline, 1 month and 2 months). Labs are not covered.
The clinic visits, printed information, carb-counting book, case of KetoCal powder/formula, and Ketostix are free.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
Patients will receive the modified Atkins diet in combination with a 10 oz KetoCal shake for the first month. The second month no shake will be given. Results at 1 month will be compared to 2 months, as well as to historical controls with the modified Atkins diet.
Modified Atkins diet and KetoCal
10 gram per day Modified Atkins diet and 10 oz per day of KetoCal shake.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Modified Atkins diet and KetoCal
10 gram per day Modified Atkins diet and 10 oz per day of KetoCal shake.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least daily seizures (or 7 per week). All seizure types allowed
* Tried at least two anticonvulsants
Exclusion Criteria
* Significantly underweight (BMI ≤ 5%)
* Prior use of the modified Atkins diet for ≥ 2 days
* Prior use of KetoCal® at any time for any duration
* Use of the KD within the past year
* Kidney disease
* History of hypercholesterolemia(\>300 mg/dl) or hypertriglyceridemia (\>200 mg/dl)
* Metabolic or mitochondrial disorder
* Aversion to shakes or inability to eat solid food
3 Years
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nutricia, Inc.
INDUSTRY
Johns Hopkins University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Johns Hopkins University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eric H Kossoff, MD
Role: PRINCIPAL_INVESTIGATOR
Johns Hopkins University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Johns Hopkins Hospital
Baltimore, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kossoff EH, Laux LC, Blackford R, Morrison PF, Pyzik PL, Hamdy RM, Turner Z, Nordli DR Jr. When do seizures usually improve with the ketogenic diet? Epilepsia. 2008 Feb;49(2):329-33. doi: 10.1111/j.1528-1167.2007.01417.x. Epub 2007 Nov 19.
Kossoff EH, Turner Z, Bluml RM, Pyzik PL, Vining EP. A randomized, crossover comparison of daily carbohydrate limits using the modified Atkins diet. Epilepsy Behav. 2007 May;10(3):432-6. doi: 10.1016/j.yebeh.2007.01.012. Epub 2007 Feb 26.
Kossoff EH, McGrogan JR, Bluml RM, Pillas DJ, Rubenstein JE, Vining EP. A modified Atkins diet is effective for the treatment of intractable pediatric epilepsy. Epilepsia. 2006 Feb;47(2):421-4. doi: 10.1111/j.1528-1167.2006.00438.x.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NA_00017953
Identifier Type: -
Identifier Source: org_study_id